Molecular Targeted Therapy in Prevalent Tumors: Learning from the Past and Future Perspectives

Author(s): Otto Metzger-Filho, Camilo Moulin, Ahmad Awada

Journal Name: Current Clinical Pharmacology
Continued as Current Reviews in Clinical and Experimental Pharmacology

Volume 5 , Issue 3 , 2010


Important advances have been achieved with molecular targeted agents in clinical oncology. Breast, colon, and lung cancer, are now commonly treated with a combination of chemotherapy and targeted agents. In this article the authors discuss the limitations of targeted therapy development, failures of previous studies, and possible strategies for an intelligent drug development. Initial attempts to block mTOR in breast cancer, the magnitude of benefit obtained with anti-EGFR therapy in lung cancer, and the narrowing use of anti-EGFR therapy in colon cancer based on K-RAS status are discussed.

Keywords: Targeted therapy, breast cancer, lung cancer, colorectal cancer, resistance, therapy individualization

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Published on: 01 March, 2012
Page: [166 - 177]
Pages: 12
DOI: 10.2174/157488410791498716
Price: $65

Article Metrics

PDF: 9